IHS Chemical Week

People & Business :: M&A

Bayer bids to acquire Norwegian pharma company Algeta

1:29 PM MST | November 26, 2013 | Natasha Alperowicz

The board of directors of Algeta (Oslo) today announced that it has received a preliminary acquisition proposal from Bayer. Bayer has offered to pay 336 Norwegian Krone per Algeta share, valuing the bid at $2.4 billion. Algeta is Bayer’s partner in a new prostate cancer treatment. Algeta says discussions are at an early stage and further announcements may be made in due course.   Bayer and Algeta are partners in Xofigo, which was approved by the US FDA on 15 May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa